Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 - GlobalData

Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 - GlobalData
Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
Published Nov 01, 2016
134 pages — Published Nov 01, 2016
Price US$ 4,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's Medical Devices sector report, Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2016' provides an overview of Melanoma Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Melanoma Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Melanoma Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Melanoma Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Melanoma Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

  
Source:
Document ID
GDME0238EPD
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents28
  1.1 List of Tables63
  1.2 List of Figures91
2 Introduction101
  2.1 Melanoma Diagnostic Tests Overview101
3 Products under Development115
  3.1 Melanoma Diagnostic Tests - Pipeline Products by Stage of Development111
  3.2 Melanoma Diagnostic Tests - Pipeline Products by Territory121
  3.3 Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path131
  3.4 Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date141
  3.5 Melanoma Diagnostic Tests - Ongoing Clinical Trials151
4 Melanoma Diagnostic Tests - Pipeline Products under Development by Companies164
  4.1 Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development162
  4.2 Melanoma Diagnostic Tests - Pipeline Products by Stage of Development182
5 Melanoma Diagnostic Tests Companies and Product Overview2059
  5.1 Abbott Diagnostics Company Overview201
    5.1.1 Abbott Diagnostics Pipeline Products &Ongoing Clinical Trials Overview202
  5.2 Adaptive Biotechnologies Corporation Company Overview221
    5.2.1 Adaptive Biotechnologies Corporation Pipeline Products &Ongoing Clinical Trials Overview221
  5.3 Agilent Technologies, Inc. Company Overview231
    5.3.1 Agilent Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview232
  5.4 BioMark Diagnostics Inc. Company Overview251
    5.4.1 BioMark Diagnostics Inc. Pipeline Products &Ongoing Clinical Trials Overview251
  5.5 BioMarker Strategies, LLC Company Overview261
    5.5.1 BioMarker Strategies, LLC Pipeline Products &Ongoing Clinical Trials Overview262
  5.6 Biosceptre (Aust) Pty Ltd Company Overview281
    5.6.1 Biosceptre (Aust) Pty Ltd Pipeline Products &Ongoing Clinical Trials Overview281
  5.7 Bio-Techne Corp Company Overview291
    5.7.1 Bio-Techne Corp Pipeline Products &Ongoing Clinical Trials Overview292
  5.8 Boston University Company Overview311
    5.8.1 Boston University Pipeline Products &Ongoing Clinical Trials Overview311
  5.9 Ceres Nanosciences, Inc. Company Overview321
    5.9.1 Ceres Nanosciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview321
  5.10 Dana-Farber Cancer Institute, Inc. Company Overview331
    5.10.1 Dana-Farber Cancer Institute, Inc. Pipeline Products &Ongoing Clinical Trials Overview331
  5.11 Digna Biotech, S.L. Company Overview341
    5.11.1 Digna Biotech, S.L. Pipeline Products &Ongoing Clinical Trials Overview341
  5.12 Exosomics Siena SpA Company Overview351
    5.12.1 Exosomics Siena SpA Pipeline Products &Ongoing Clinical Trials Overview351
  5.13 Genentech, Inc. Company Overview361
    5.13.1 Genentech, Inc. Pipeline Products &Ongoing Clinical Trials Overview361
  5.14 Genomic Health, Inc. Company Overview371
    5.14.1 Genomic Health, Inc. Pipeline Products &Ongoing Clinical Trials Overview372
  5.15 Hospital Universitario Cruces Company Overview391
    5.15.1 Hospital Universitario Cruces Pipeline Products &Ongoing Clinical Trials Overview391
  5.16 Hummingbird Diagnostics GmbH Company Overview401
    5.16.1 Hummingbird Diagnostics GmbH Pipeline Products &Ongoing Clinical Trials Overview401
  5.17 ImmunID Company Overview411
    5.17.1 ImmunID Pipeline Products &Ongoing Clinical Trials Overview414
  5.18 Institut Pasteur Company Overview451
    5.18.1 Institut Pasteur Pipeline Products &Ongoing Clinical Trials Overview451
  5.19 InterGenetics Incorporated Company Overview461
    5.19.1 InterGenetics Incorporated Pipeline Products &Ongoing Clinical Trials Overview461
  5.20 IV Diagnostics, Inc. Company Overview471
    5.20.1 IV Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview471
  5.21 John Hopkins University Company Overview481
    5.21.1 John Hopkins University Pipeline Products &Ongoing Clinical Trials Overview481
  5.22 Louisville Bioscience, Inc. Company Overview491
    5.22.1 Louisville Bioscience, Inc. Pipeline Products &Ongoing Clinical Trials Overview491
  5.23 MDNA Life Sciences, Inc. Company Overview501
    5.23.1 MDNA Life Sciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview501
  5.24 Melanovus Oncology, Inc. Company Overview511
    5.24.1 Melanovus Oncology, Inc. Pipeline Products &Ongoing Clinical Trials Overview511
  5.25 Memorial Sloan Kettering Cancer Center Company Overview521
    5.25.1 Memorial Sloan Kettering Cancer Center Pipeline Products &Ongoing Clinical Trials Overview521
  5.26 MyCardio,LLC. Company Overview531
    5.26.1 MyCardio,LLC. Pipeline Products &Ongoing Clinical Trials Overview531
  5.27 Myriad Genetics, Inc. Company Overview541
    5.27.1 Myriad Genetics, Inc. Pipeline Products &Ongoing Clinical Trials Overview542
  5.28 Orion Genomics LLC Company Overview561
    5.28.1 Orion Genomics LLC Pipeline Products &Ongoing Clinical Trials Overview561
  5.29 Oryzon Genomics SA Company Overview571
    5.29.1 Oryzon Genomics SA Pipeline Products &Ongoing Clinical Trials Overview572
  5.30 Pacific Edge Limited Company Overview591
    5.30.1 Pacific Edge Limited Pipeline Products &Ongoing Clinical Trials Overview592
  5.31 Protea Biosciences Group, Inc. Company Overview611
    5.31.1 Protea Biosciences Group, Inc. Pipeline Products &Ongoing Clinical Trials Overview612
  5.32 Qiagen N.V. Company Overview631
    5.32.1 Qiagen N.V. Pipeline Products &Ongoing Clinical Trials Overview632
  5.33 Roche Diagnostics International Ltd. Company Overview651
    5.33.1 Roche Diagnostics International Ltd. Pipeline Products &Ongoing Clinical Trials Overview654
  5.34 Rosetta Genomics Ltd Company Overview691
    5.34.1 Rosetta Genomics Ltd Pipeline Products &Ongoing Clinical Trials Overview692
  5.35 Sividon Diagnostics GmbH Company Overview711
    5.35.1 Sividon Diagnostics GmbH Pipeline Products &Ongoing Clinical Trials Overview711
  5.36 SomaLogic, Inc. Company Overview721
    5.36.1 SomaLogic, Inc. Pipeline Products &Ongoing Clinical Trials Overview721
  5.37 University of California, San Francisco Company Overview731
    5.37.1 University of California, San Francisco Pipeline Products &Ongoing Clinical Trials Overview731
  5.38 University of Colorado Company Overview741
    5.38.1 University of Colorado Pipeline Products &Ongoing Clinical Trials Overview741
  5.39 University of Louisville Company Overview751
    5.39.1 University of Louisville Pipeline Products &Ongoing Clinical Trials Overview751
  5.40 University of Maryland, Baltimore Company Overview761
    5.40.1 University of Maryland, Baltimore Pipeline Products &Ongoing Clinical Trials Overview761
  5.41 Vanderbilt University Company Overview771
    5.41.1 Vanderbilt University Pipeline Products &Ongoing Clinical Trials Overview771
  5.42 Zymera, Inc Company Overview781
    5.42.1 Zymera, Inc Pipeline Products &Ongoing Clinical Trials Overview781
6 Melanoma Diagnostic Tests - Recent Developments7952
  6.1 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare791
  6.2 Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy791
  6.3 Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results802
  6.4 Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline821
  6.5 Sep 15, 2016: Agilent Technologies Raises USD300 Million in Public Offering of Notes Due 2026821
  6.6 Sep 01, 2016: Novel Test Distinguishes Atypical Moles From Melanoma821
  6.7 Aug 31, 2016: bioMerieux - First-Half 2016 Results834
  6.8 Aug 29, 2016: Dr. Ann Hanham Joins HTG Molecular Diagnostics Board of Directors871
  6.9 Aug 17, 2016: Agilent Technologies Reports Third-Quarter 2016 Results871
  6.10 Aug 16, 2016: Protea Announces Second Quarter 2016 Results881
  6.11 Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results891
  6.12 Aug 09, 2016: HTG Molecular Diagnostics Reports Second Quarter 2016 Results901
  6.13 Aug 08, 2016: Oryzon Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016911
  6.14 Aug 02, 2016: Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance912
  6.15 Jul 28, 2016: QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017933
  6.16 Jul 27, 2016: GSK announces significant new investment in UK manufacturing network961
  6.17 Jul 27, 2016: GlaxoSmithKline: Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 20169716
  6.18 Jul 21, 2016: Quest Diagnostics Reports Second Quarter 2016 Financial Results1131
  6.19 Jul 18, 2016: bioMerieux Second-Quarter 2016 Business Review1143
  6.20 Jul 07, 2016: GSK and Save the Children call for developing country innovations to enter $1 million award1171
  6.21 Jul 06, 2016: Bio-Techne Acquires Advanced Cell Diagnostics1181
  6.22 Jul 05, 2016: MolecularMD Raises USD0.5 Million in Venture Financing1181
  6.23 Jul 04, 2016: Exiqon Nomination of candidates for the supervisory board1181
  6.24 Jun 23, 2016: HTG Molecular Diagnostics Announces VERI/O Laboratory Service1181
  6.25 Jun 20, 2016: HTG Molecular Appoints New Vice President of North American Capital Sales for the HTG EdgeSeq Platform1191
  6.26 Jun 15, 2016: Quest Diagnostics and Safeway Team to Offer Convenient Diagnostic Testing to Customers in More States1191
  6.27 Jun 14, 2016: GlaxoSmithKline: Executive Director Change1201
  6.28 Jun 02, 2016: Pacific Edge Board Changes Announced1201
  6.29 May 31, 2016: Myriad Genetics Acquires Sividon Diagnostics1211
  6.30 May 31, 2016: Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals1211
  6.31 May 27, 2016: Protea Biosciences to Raise Funds through Public Offering of Shares1211
  6.32 May 23, 2016: Quest Diagnostics Raises USD500 Million in Public Offering of 3.45% Senior Notes due 20261211
  6.33 May 20, 2016: International Comparison of BRAF Testing in Melanoma Abstract Released in Conjunction With ASCO 20161221
  6.34 May 20, 2016: Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company1221
  6.35 May 16, 2016: Agilent Technologies Reports Second-Quarter 2016 Results1231
  6.36 May 16, 2016: Protea Announces First Quarter 2016 Results1241
  6.37 May 12, 2016: Oryzon Reports First Quarter 2016 Financial Results and Corporate Update1241
  6.38 May 12, 2016: HTG Molecular Diagnostics Reports First Quarter 2016 Results1251
  6.39 May 11, 2016: Dako, an Agilent Technologies Company, Announces Expanded Use of PD-L1 Diagnostic Test in Europe1251
  6.40 Apr 25, 2016: Protea Biosciences Enters into Licensing Agreement with Yale University1261
  6.41 Mar 31, 2016: ImmunTraCkeR Results on Prediction of Response to Cancer Immunotherapy Selected for Presentation at ASCO Annual Meeting1261
  6.42 Mar 15, 2016: Myriad Presents Second Pivotal Validation Study for Its myPath Melanoma Test1261
  6.43 Feb 23, 2016: ImmunID Signs Master Collaboration Agreement with MSK about the Prediction of Response to Immuno-Oncology Agents Using ImmunTraCkeR1271
  6.44 Feb 15, 2016: Collaboration led by ImmunID Awarded Innovate UK Grant to Advance Program on Prediction of Response to Cancer Immunotherapy using ImmunTraCkeR1281
  6.45 Jan 25, 2016: Quest Diagnostics Expands Dako's PD-L1 IHC 28-8 Complementary Test to Include Melanoma1281
  6.46 Jan 25, 2016: Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma1291
  6.47 Jan 11, 2016: Blood Test that Monitors Dead Cancer Cell DNA Better at Tracking Spread of Melanoma1301
7 Appendix1314
  7.1 Methodology1312
  7.2 About GlobalData1331
  7.3 Contact Us1331
  7.4 Disclaimer1341

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" Nov 01, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/GlobalData/Melanoma-Diagnostic-Tests-Medical-Devices-Pipeline-Assessment-2016-2085-23767>
  
APA:
GlobalData. (2016). Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Nov 01, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/Melanoma-Diagnostic-Tests-Medical-Devices-Pipeline-Assessment-2016-2085-23767>
  
US$ 4,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.